Physician profile
Robert Drenchko
NPI 1396179073
$8,825.05
in general payments reported to CMS, 2019-2025
29 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $36.61 · 2022: $334 · 2023: $4,596 · 2024: $3,120 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,151 · Food and Beverage: $780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,150.57 |
| Food and Beverage | $779.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $7,356.41 | 2022-2024 | Nexplanon |
| Therapeuticsmd, INC. | $171.99 | 2019-2022 | |
| Amgen INC. | $131.50 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.05 | 2019-2025 | |
| Daiichi Sankyo INC. | $111.21 | 2019-2024 | Injectafer |
| Astellas Pharma US INC | $103.29 | 2023-2025 | Veozah |
| Gynesonics, INC. | $98.01 | 2022-2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Exeltis, USA INC. | $77.17 | 2022-2023 | Slynd |
| Sumitomo Pharma America, INC. | $75.51 | 2023-2025 | Myfembree, Gemtesa |
| Hologic Sales and Service, LLC | $58.05 | 2022-2023 | Myosure Tissue Removal Device, Acessa Provu System |
| Abbvie INC. | $57.96 | 2019 | |
| Pfizer INC. | $53.89 | 2023-2024 | |
| Myriad Women'S Health, INC. | $51.86 | 2023 | Myrisk |
| Exact Sciences Corporation | $38.15 | 2025 | The Cologuard Plus Collection Kit |
| Roche Diagnostics Corporation | $35.12 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $32.95 | 2025 | Pyrukynd |
| Mayne Pharma Commercial LLC | $32.92 | 2022-2023 | |
| Becton, Dickinson and Company | $30.30 | 2022 | |
| Millicent US INC | $23.66 | 2025 | Intrarosa |
| Merck Sharp & Dohme LLC | $22.86 | 2019 | |
| Medtronic, INC. | $22.40 | 2025 | Truclear |
| Sage Therapeutics, LLC | $21.52 | 2024 | |
| Shield Therapeutics INC | $17.05 | 2023 | Accrufer |
| Coopersurgical, INC. | $16.32 | 2025 | Paragard T 380a |
| Optumhealth Care Solutions, LLC | $16.01 | 2024 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Boston Scientific Corporation | $14.34 | 2019 | |
| Baxter Healthcare | $13.64 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.00 | 2019 | |
| Mylan Pharmaceuticals INC. | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Drenchko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.